Warren A Dorsch

20130190289, Jul 25, 2013

Dec 21, 2012

13/723668

Vertex Pharmaceuticals Incorporated - Cambridge MA, US
Dean M. Wilson - Bedford MA, US
Laval Chan Chun Kong - Kirkland, CA
Sanjoy Kumar Das - Pierrefonds, CA
Carl Poisson - Montreal, CA
John J. Court - Littleton MA, US
Qing Tang - Acton MA, US
Pan Li - Lexington MA, US
Philip N. Collier - Arlington MA, US
Nathan Waal - Cambridge MA, US
David J. Lauffer - Stow MA, US
Warren Dorsch - Providence RI, US

Vertex Pharmaceuticals Incorporated - Cambridge MA

C07D 413/12
C07D 409/12
C07D 333/38

51421018, 549480, 514447, 548527, 514422, 544146, 5142315, 548952, 540524, 51421208, 540488, 51421103, 435184

A compound is represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the variables of Structural Formula (I) are as described in the specification and the claims. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier of excipient. A method of treating a HCV infection in a subject comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting or reducing the activity of HCV polymerase in a subject or in a biological in vitro sample comprises administering to the subject or to the sample a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

20220363685, Nov 17, 2022

Mar 1, 2021

17/188132

- Boston MA, US
Guy BEMIS - Boston MA, US
Michael BOYD - Boston MA, US
David DEININGER - Boston MA, US
Hongbo DENG - Southborough MA, US
Warren DORSCH - Boston MA, US
Wenxin GU - Concord MA, US
Russell R. HOOVER - Harvard MA, US
Mark Willem LEDEBOER - Boston MA, US
Brian LEDFORD - Boston MA, US
Francois MALTAIS - Boston MA, US
Marina PENNEY - Acton MA, US
Darin TAKEMOTO - Belmont MA, US
Nathan D. WAAL - Cambridge MA, US
Tiansheng WANG - Concord MA, US
Pan LI - Lexington MA, US

C07D 487/04
C07D 491/20
C07D 487/14
C07D 519/00
C07D 471/14
C07D 498/04
C07D 471/04

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

20220340523, Oct 27, 2022

Jan 28, 2021

17/161474

- Boston MA, US
Timothy J. SENTER - Arlington MA, US
Jingrong CAO - Newton MA, US
Jon H. COME - Cambridge MA, US
Francois DENIS - St-Lazare, CA
Warren A. DORSCH - Waltham MA, US
Anne FORTIER - Jamaica Plain MA, US
Martine HAMEL - Laval, CA
Elaine B. KRUEGER - Milton MA, US
Brian LEDFORD - Norton MA, US
Francois MALTAIS - Stoneham MA, US
Suganthini S. NANTHAKUMAR - Newton MA, US
Olivier NICOLAS - Montreal, CA
Camil E. SAYEGH - Belmont MA, US
Tiansheng WANG - Concord MA, US

C07D 209/18
C07D 403/12
C07D 405/12
C07D 413/12
C07D 401/12
C07D 403/14
C07D 451/02
C07D 491/107
C07D 403/04

The disclosure provides at least one entity chosen from compounds of Formula (I)pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

20230014907, Jan 19, 2023

Jun 11, 2021

17/345256

- Boston MA, US
Timothy J. Senter - Arlington MA, US
Jingrong Cao - Newton MA, US
Jon H. Come - Cambridge MA, US
Francois Denis - St-Lazare, CA
Warren A. Dorsch - Waltham MA, US
Anne Fortier - Jamaica Plain MA, US
Martine Hamel - Laval, CA
Elaine B. Krueger - Milton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Stoneham MA, US
Suganthini S. Nanthakumar - Newton MA, US
Olivier Nicolas - Montreal, CA
Camil E. Sayegh - Belmont MA, US
Tiansheng Wang - Concord MA, US

C07D 209/18
C07D 403/12
C07D 405/12
C07D 401/12
C07D 403/06
C07D 413/12
C07D 401/06
C07D 417/12
C07D 409/12
C07D 209/40
C07D 209/16
C07D 209/12

The disclosure provides compounds of Formula I,deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

20230011118, Jan 12, 2023

Jun 11, 2021

17/345268

- Boston MA, US
Timothy J. Senter - Arlington MA, US
Jingrong Cao - Newton MA, US
Jon H. Come - Cambridge MA, US
Francois Denis - St-Lazare, CA
Warren A. Dorsch - Waltham MA, US
Anne Fortier - Jamaica Plain MA, US
Martine Hamel - Laval, CA
Elaine B. Krueger - Milton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Stoneham MA, US
Suganthini S. Nanthakumar - Newton MA, US
Olivier Nicolas - Montreal, CA
Camil E. Sayegh - Belmont MA, US
Tiansheng Wang - Concord MA, US

C07D 403/12
C07D 209/14
C07D 403/08
C07D 405/12
C07D 409/12
C07D 401/12
C07D 471/04
C07D 413/12
C07D 417/12

The disclosure provides at least one compound, reiterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), reiterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

20200377479, Dec 3, 2020

Dec 17, 2019

16/717099

- Boston MA, US
Jon H. COME - Cambridge MA, US
Leslie A. DAKIN - Framingham MA, US
Francois DENIS - Boston MA, US
Warren A. DORSCH - Waltham MA, US
Anne FORTIER - Jamaica Plain MA, US
Martine HAMEL - Boston MA, US
Elaine B. KRUEGER - Milton MA, US
Brian LEDFORD - Norton MA, US
Suganthini S. NANTHAKUMAR - Newton MA, US
Olivier NICOLAS - Montreal, CA
Camil SAYEGH - Boston MA, US
Timothy J. SENTER - Arlington MA, US
Tiansheng WANG - Concord MA, US
Michael BRODNEY - Newton MA, US
Kan-Nian HU - Brighton MA, US
Peter Rose - Littleton MA, US
Kevin GAGNON - Burlington MA, US
Yi SHI - Natick MA, US
Muna SHRESTHA - Belmont MA, US
Ales MEDEK - Winchester MA, US
Faith WITKOS - Attleboro MA, US

C07D 403/12
C07D 405/14

The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomeulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

20190322658, Oct 24, 2019

Apr 23, 2019

16/391419

- Darmstadt, DE
- Boston MA, US
Guy Bemis - Boston MA, US
Michael Boyd - Boston MA, US
Kishan Chandupatla - Boston MA, US
Philip Collier - Boston MA, US
Hongbo Deng - Southborough MA, US
Huijun Dong - Arlington MA, US
Warren Dorsch - Boston MA, US
Russell R. Hoover - Harvard MA, US
Shashank Kukarni - Waltham MA, US
Marina Penney - Acton MA, US
Steven Ronkin - Boston MA, US
Darin Takemoto - Belmont MA, US
Qing Tang - Acton MA, US
Nathan D. Waal - Cambridge MA, US
Tiansheng Wang - Concord MA, US

C07D 413/14
A61P 35/00
C07D 417/14
C07D 403/04
C07D 401/14
C07D 413/04
C07D 491/113
C07D 491/107

The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

20190322673, Oct 24, 2019

Apr 23, 2019

16/391407

- Boston MA, US
Guy Bemis - Boston MA, US
Michael Boyd - Boston MA, US
David Deininger - Boston MA, US
Hongbo Deng - Southborough MA, US
Warren Dorsch - Boston MA, US
Wenxin Gu - Concord MA, US
Russell R. Hoover - Harvard MA, US
Mark Willem Ledeboer - Boston MA, US
Brian Ledford - Boston MA, US
Francois Maltais - Boston MA, US
Marina Penney - Acton MA, US
Darin Takemoto - Belmont MA, US
Nathan D. Waal - Cambridge MA, US
Tiansheng Weng - Concord MA, US

C07D 487/04
C07D 491/20
C07D 487/14
C07D 471/04
C07D 471/14
C07D 498/04
C07D 519/00

The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).